|
US7037922B1
(en)
|
2000-03-10 |
2006-05-02 |
Neurogen Corporation |
Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands
|
|
ATE247652T1
(de)
|
1999-03-29 |
2003-09-15 |
Neurogen Corp |
4-substituierte chinolinderivate als nk-3 und/oder gaba(a) rezeptor liganden
|
|
CA2375920A1
(en)
|
1999-06-14 |
2000-12-21 |
Eli Lilly And Company |
Compounds
|
|
WO2001029025A2
(en)
|
1999-10-19 |
2001-04-26 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
US6794393B1
(en)
|
1999-10-19 |
2004-09-21 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
US6420382B2
(en)
|
2000-02-25 |
2002-07-16 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
US6313138B1
(en)
|
2000-02-25 |
2001-11-06 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
US6521618B2
(en)
|
2000-03-28 |
2003-02-18 |
Wyeth |
3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
|
|
US6960590B2
(en)
|
2000-10-17 |
2005-11-01 |
Merck & Co. Inc. |
Orally active salts with tyrosine kinase activity
|
|
GB0028964D0
(en)
*
|
2000-11-28 |
2001-01-10 |
Smithkline Beecham Spa |
Novel compounds
|
|
WO2003037252A2
(en)
|
2001-10-30 |
2003-05-08 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
EP1541149A1
(en)
*
|
2002-06-26 |
2005-06-15 |
Kyowa Hakko Kogyo Co., Ltd. |
Phosphodiesterase inhibitor
|
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
BR122018074353B8
(pt)
|
2003-01-28 |
2023-05-02 |
Ironwood Pharmaceuticals Inc |
composição farmacêutica, polipeptídeo e métodos para a produção dos mesmos
|
|
RU2229475C1
(ru)
*
|
2003-03-06 |
2004-05-27 |
ООО "Исследовательский институт химического разнообразия |
6-сульфамоилхинолин-4-карбоновые кислоты, их производные и комбинаторная библиотека
|
|
TW201018662A
(en)
|
2005-12-12 |
2010-05-16 |
Astrazeneca Ab |
Alkylsulphonamide quinolines
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
WO2008151257A2
(en)
|
2007-06-04 |
2008-12-11 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
US20090118135A1
(en)
*
|
2007-06-08 |
2009-05-07 |
The Burnham Institute |
Methods and compounds for regulating apoptosis
|
|
ES2627848T3
(es)
|
2008-06-04 |
2017-07-31 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
|
|
ES2624828T3
(es)
|
2008-07-16 |
2017-07-17 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
|
|
CN103819403B
(zh)
|
2008-12-31 |
2017-01-04 |
阿德利克斯公司 |
用于治疗与体液潴留或盐超负荷有关的病症和胃肠道病症的化合物和方法
|
|
WO2018129556A1
(en)
|
2017-01-09 |
2018-07-12 |
Ardelyx, Inc. |
Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
US10376481B2
(en)
|
2012-08-21 |
2019-08-13 |
Ardelyx, Inc. |
Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
|
|
RU2015107019A
(ru)
|
2012-08-21 |
2016-10-10 |
Эрделикс Инк. |
Соединения и способы для ингибирования nhe-опосредованного антипорта в лечении расстройств, ассоциированных с задержкой жидкости или солевой перегрузкой и заболеваний желудочно-кишечного тракта
|
|
EP2968439A2
(en)
|
2013-03-15 |
2016-01-20 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
|
US9708367B2
(en)
|
2013-03-15 |
2017-07-18 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase and their uses
|
|
CN105392483B
(zh)
|
2013-04-12 |
2019-03-15 |
阿德利克斯公司 |
用于抑制磷酸盐转运的nhe3结合化合物和方法
|
|
BR112015026519A2
(pt)
|
2013-04-19 |
2017-07-25 |
Astrazeneca Ab |
composto antagonista do receptor nk3 (nk3ra) para uso em um método destinado ao tratamento de síndrome do ovário policístico (sop)
|
|
PL3004138T3
(pl)
|
2013-06-05 |
2024-07-29 |
Bausch Health Ireland Limited |
Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie
|
|
ES2726927T3
(es)
*
|
2014-07-08 |
2019-10-10 |
Dow Agrosciences Llc |
Proceso para la preparación de ácidos 3-hidroxipicolínicos
|
|
WO2017072629A1
(en)
|
2015-10-29 |
2017-05-04 |
Cadila Healthcare Limited |
Pharmaceutical combination of nk3 receptor antagonist and biguanides
|
|
EA201991676A1
(ru)
|
2017-01-09 |
2020-01-30 |
Арделикс, Инк. |
Ингибиторы nhe-опосредованного антипорта
|
|
KR20240090875A
(ko)
|
2017-01-09 |
2024-06-21 |
알데릭스, 인코포레이티드 |
위장관 장애를 치료하는 데 유용한 화합물
|
|
CN113194948A
(zh)
*
|
2018-11-15 |
2021-07-30 |
国立大学法人九州大学 |
Il-31介导性疾病的预防或治疗剂及医药组合物
|